NCT01807377View on ClinicalTrials.gov

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

PF-05175157

200 mg tablet administered twice per day for 14 days

DRUG

Midazolam

2mg administered as single doses on Days 0 and 11

OTHER

Placebo

Placebo administered twice per day for 14 days

DRUG

Midazolam

2mg administered as single doses on Days 0 and 11

Trial Locations (1)

91911

Pfizer Investigational Site, Chula Vista

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY